Pazopanib Side Effects and Management
Pazopanib causes serious and potentially life-threatening adverse effects that require intensive monitoring, with hepatotoxicity, hypertension, and cardiovascular toxicity being the most critical concerns requiring immediate intervention. 1
Serious/Life-Threatening Side Effects
Hepatotoxicity (Most Critical)
- Elevated transaminases occur in up to 63.64% of patients, with severe liver injury requiring treatment interruption in >10% of cases 1, 2
- Recent pharmacokinetic data identifies a critical threshold: trough concentrations >34 mg/L increase liver toxicity risk 3.35-fold 3
- Monitor liver function tests within 1 week of starting therapy, then frequently during first months
- If severe transaminase elevations occur, discontinue pazopanib immediately and consider stopping concurrent statins (pazopanib-simvastatin interaction significantly increases hepatotoxicity risk) 4
Hypertension
- Occurs in 31.82-37% of patients, with sudden severe rises that can be life-threatening 1, 5, 2
- Blood pressure increases typically manifest within the first several months of treatment 1
- Check blood pressure within 1 week of starting pazopanib, then frequently throughout treatment
- Ensure blood pressure is well-controlled before initiating therapy 1
- Emergency symptoms requiring immediate medical attention: severe chest pain, severe headache, blurred vision, confusion, seizures, or loss of consciousness 1
Posterior Reversible Encephalopathy Syndrome (PRES)
- Can cause death - presents with headaches, seizures, confusion, hypertension, vision changes, speech loss 1
- Requires immediate treatment discontinuation
Cardiovascular Toxicity
- QT interval prolongation and other cardiovascular events are well-documented 6
- Mechanisms remain incompletely understood but warrant cardiac monitoring
Tumor Lysis Syndrome (TLS)
- Can be fatal - caused by rapid cancer cell breakdown 1
- Monitor for: irregular heartbeat, seizures, confusion, muscle cramps/spasms, decreased urine output
- Requires blood test monitoring
Common Side Effects (Frequency Data)
Gastrointestinal
- Diarrhea (31.82-33%) - most common overall 5, 2
- Nausea/vomiting (18.18-34%) 5, 2
- Anorexia/loss of appetite 1, 7
- Stomach pain 1
Other Frequent Effects
- Fatigue (27.27-51%) 8, 2
- Hair color changes/depigmentation 1, 7
- Hypertension (31.82-37%) 5, 2
- Hypothyroidism (18.18%) - requires thyroid function monitoring 4, 2
- Proteinuria (22.73%) - may require treatment discontinuation if severe 1, 2
- Hand-foot skin reaction (22.73%) 2
- Headache, taste changes, trouble breathing, skin color changes 1
Laboratory Abnormalities
Serious Infections
- Can cause death 1
- Monitor for: fever, persistent cold symptoms, flu symptoms, painful urination, infected wounds
Pneumothorax (Collapsed Lung)
- Can occur with pazopanib - presents as sudden shortness of breath 1
Critical Drug Interactions
Avoid CYP3A4 inhibitors and inducers - pazopanib is primarily metabolized by CYP3A4 4, 7
- Statins (especially simvastatin): significantly increase hepatotoxicity risk - consider discontinuation 4
- Voriconazole, dexamethasone, prednisolone: alter pazopanib metabolism 4
- Food effect: 2-fold increase in AUC with high-fat meals - take on empty stomach (1 hour before or 2 hours after meals) 7
- Do not crush tablets - causes 2-fold AUC increase 7
Dose Modification Strategy
Recent evidence supports starting at 600 mg daily rather than the FDA-labeled 800 mg to reduce toxicity while maintaining efficacy 3:
- Target therapeutic window: trough concentrations 20-34 mg/L
- Treatment interruptions occur in 45% and dose reductions in 30% of patients 8
- Real-world practice shows median starting doses of 300 mg daily (range 200-800 mg) with similar efficacy to full-dose trials 8
Comparative Toxicity Profile
Pazopanib shows higher rates of nausea, diarrhea, and hypertension compared to sorafenib and sunitinib, but significantly lower rates of hand-foot syndrome, rash, and mucositis compared to sorafenib 5. Sunitinib causes more severe mucositis (7.6% grade ≥3 vs 1.3% with pazopanib) 5.